LINDSAY VAN DAM: Open Payments
NPI 1659840767 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$496 in 27 payments from 9 companies in 2025. Trend: 2023 $1,843 · 2024 $1,497 · 2025 $496
Food & beverage: $496
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| GENZYME CORPORATION | 2 | $48 |
| Janssen Biotech, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $30 |
| Gilead Sciences, Inc. | 1 | $21 |
| Biocon Biologics Inc | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
Products named: LINZESS, RINVOQ, ENTYVIO, DUPIXENT, TREMFYA, OMVOH, MAVYRET, Yesintek.
Industry payments across AZ — which companies pay providers there.
